{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T08:08:58Z","timestamp":1712995738935},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Headache recurrence is a common feature of acute therapies, whether approved or still in development, and continues to be a significant problem for both the patient and the clinician. Further complicating this issue is lack of standardization in definitions of recurrence used in clinical trials, as well as disparity in patient characteristics, rendering a comparison of different acute medications challenging. Recurrence has serious clinical implications, which can include an increased risk for new-onset chronic migraine and\/or development of medication overuse headache. The aim of this review is to illustrate variability of recurrence rates depending on prevailing definitions in the literature for widely used acute treatments for migraine and to emphasize sustained response as a clinically relevant endpoint for measuring prolonged efficacy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Body<\/jats:title>\n                <jats:p>A literature search of PubMed for articles of approved acute therapies for migraine that reported recurrence rates was performed. Study drugs of interest included select triptans, gepants, lasmiditan, and dihydroergotamine mesylate. An unpublished post hoc analysis of an investigational dihydroergotamine mesylate product that evaluated recurrence rates using several different definitions of recurrence common in the literature is also included. Depending on the criteria established by the clinical trial and the definition of recurrence used, rates of recurrence vary considerably across different acute therapies for migraine, making it difficult to compare results of different trials to assess the sustained (i.e., over a single attack) and the prolonged (i.e., over multiple attacks) efficacy of a particular study medication.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>A standardized definition of recurrence is necessary to help physicians evaluate recurrence rates of different abortive agents for migraine. Sustained pain relief or freedom may be more comprehensive efficacy outcome measures than recurrence. Future efficacy studies should be encouraged to use the recommended definition of sustained pain freedom set by the International Headache Society.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-022-01519-4","type":"journal-article","created":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T01:27:20Z","timestamp":1669166840000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Variability in recurrence rates with acute treatments for migraine: why recurrence is not an appropriate outcome measure"],"prefix":"10.1186","volume":"23","author":[{"given":"Stewart J.","family":"Tepper","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Ailani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sutapa","family":"Ray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joe","family":"Hirman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen B.","family":"Shrewsbury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheena K.","family":"Aurora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,22]]},"reference":[{"key":"1519_CR1","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s10194-008-0052-8","volume":"9","author":"F Antonaci","year":"2008","unstructured":"Antonaci F, Sances G, Guaschino E, De Cillis I, Bono G, Nappi G (2008) Meeting patient expectations in migraine treatment: what are the key endpoints? J Headache Pain 9:207\u2013213. https:\/\/doi.org\/10.1007\/s10194-008-0052-8","journal-title":"J Headache Pain"},{"key":"1519_CR2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1177\/0333102419828967","volume":"39","author":"HC Diener","year":"2019","unstructured":"Diener HC, Tassorelli C, Dodick DW, Silberstein SD, Lipton RB, Ashina M et al (2019) Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: fourth edition. Cephalalgia 39:687\u2013710. https:\/\/doi.org\/10.1177\/0333102419828967","journal-title":"Cephalalgia"},{"key":"1519_CR3","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/s0140-6736(01)06711-3","volume":"358","author":"MD Ferrari","year":"2001","unstructured":"Ferrari MD, Roon KI, Lipton RB, Goadsby PJ (2001) Oral triptans (serotonin 5-HT(1B\/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 358:1668\u20131675. https:\/\/doi.org\/10.1016\/s0140-6736(01)06711-3","journal-title":"Lancet"},{"key":"1519_CR4","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1111\/j.1526-4610.1999.00006.x","volume":"39","author":"RB Lipton","year":"1999","unstructured":"Lipton RB, Stewart WF (1999) Acute migraine therapy: do doctors understand what patients with migraine want From therapy? Headache 39:S20\u2013S26. https:\/\/doi.org\/10.1111\/j.1526-4610.1999.00006.x","journal-title":"Headache"},{"key":"1519_CR5","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/j.1526-4610.2007.00752.x","volume":"47","author":"M Bigal","year":"2007","unstructured":"Bigal M, Rapoport A, Aurora S, Sheftell F, Tepper S, Dahlof C (2007) Satisfaction with current migraine therapy: experience from 3 centers in US and Sweden. Headache 47:475\u2013479. https:\/\/doi.org\/10.1111\/j.1526-4610.2007.00752.x","journal-title":"Headache"},{"key":"1519_CR6","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1046\/j.1468-2982.2002.00435.x","volume":"22","author":"NC Santanello","year":"2002","unstructured":"Santanello NC, Davies G, Allen C, Kramer M, Lipton R (2002) Determinants of migraine-specific quality of life. Cephalalgia 22:680\u2013685. https:\/\/doi.org\/10.1046\/j.1468-2982.2002.00435.x","journal-title":"Cephalalgia"},{"key":"1519_CR7","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1136\/jnnp.58.4.508","volume":"58","author":"T Catarci","year":"1995","unstructured":"Catarci T, Lenzi G, Cerbo R, Fieschi C (1995) Sumatriptan and daily headache. J Neurol Neurosurg Psychiatry 58:508. https:\/\/doi.org\/10.1136\/jnnp.58.4.508","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1519_CR8","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/s0140-6736(97)11370-8","volume":"351","author":"MD Ferrari","year":"1998","unstructured":"Ferrari MD (1998) Migraine. Lancet 351:1043\u20131051. https:\/\/doi.org\/10.1016\/s0140-6736(97)11370-8","journal-title":"Migraine Lancet"},{"key":"1519_CR9","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1046\/j.1468-2982.2002.00404.x","volume":"22","author":"MD Ferrari","year":"2002","unstructured":"Ferrari MD, Goadsby PJ, Roon KI, Lipton RB (2002) Triptans (serotonin, 5-HT1B\/1D agonists) in migraine: Detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 22:633\u2013658. https:\/\/doi.org\/10.1046\/j.1468-2982.2002.00404.x","journal-title":"Cephalalgia"},{"key":"1519_CR10","unstructured":"Atlas SJ, Touchette DR, Agboola F, Lee TA, Chapman R, Pearson SD et al (2020) Acute treatments for migraine: effectiveness and value. Institute for Clinical and Economic Review. http:\/\/icer-review.org\/material\/acute-migraine-evidence-report\/. Accessed 2 Feb 2022"},{"key":"1519_CR11","unstructured":"National Headache Foundation (2008) Experts answer your questions: new warnings on Imitrex? https:\/\/headaches.org\/2008\/06\/06\/experts-answer-your-questions-national-headache-awareness-week-2\/. Accessed 2 Feb 2022."},{"key":"1519_CR12","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1212\/wnl.0000000000001256","volume":"84","author":"RB Lipton","year":"2015","unstructured":"Lipton RB, Fanning KM, Serrano D, Reed ML, Cady R, Buse DC (2015) Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology 84:688\u2013695. https:\/\/doi.org\/10.1212\/wnl.0000000000001256","journal-title":"Neurology"},{"key":"1519_CR13","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s11940-002-0043-z","volume":"4","author":"SK Aurora","year":"2002","unstructured":"Aurora SK, Dempsey J (2002) Headache recurrence and treatment. Curr Treat Options Neurol 4:335\u2013342. https:\/\/doi.org\/10.1007\/s11940-002-0043-z","journal-title":"Curr Treat Options Neurol"},{"key":"1519_CR14","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1046\/j.1526-4610.1998.3803184.x","volume":"38","author":"V Pfaffenrath","year":"1998","unstructured":"Pfaffenrath V, Cunin G, Sjonell G, Prendergast S (1998) Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan. Headache 38:184\u2013190. https:\/\/doi.org\/10.1046\/j.1526-4610.1998.3803184.x","journal-title":"Headache"},{"key":"1519_CR15","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1811090","volume":"381","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M et al (2019) Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med 381:142\u2013149. https:\/\/doi.org\/10.1056\/NEJMoa1811090","journal-title":"N Engl J Med"},{"key":"1519_CR16","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1111\/head.13551","volume":"59","author":"D Yarnitsky","year":"2019","unstructured":"Yarnitsky D, Dodick DW, Grosberg BM, Burstein R, Ironi A, Harris D et al (2019) Remote electrical neuromodulation (REN) relieves acute migraine: a randomized, double-blind, placebo-controlled, multicenter trial. Headache 59:1240\u20131252. https:\/\/doi.org\/10.1111\/head.13551","journal-title":"Headache"},{"key":"1519_CR17","unstructured":"Nurtec ODT [prescribing information] (2021)\u00a0Biohaven Pharmaceuticals, Inc, New Haven.\u00a0https:\/\/biohaven-nurtec-consumer-assets.s3.amazonaws.com\/nurtec-prescribing-information.pdf. Accessed 2 Feb 2022."},{"key":"1519_CR18","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/j.1526-4610.2011.01869.x","volume":"51","author":"SK Aurora","year":"2011","unstructured":"Aurora SK, Silberstein SD, Kori SH, Tepper SJ, Borland SW, Wang M et al (2011) MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine. Headache 51:507\u2013517. https:\/\/doi.org\/10.1111\/j.1526-4610.2011.01869.x","journal-title":"Headache"},{"issue":"Suppl 1","key":"1519_CR19","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s10194-010-0259-3","volume":"11","author":"S Tepper","year":"2010","unstructured":"Tepper S, Kori S, Goadsby P et al (2010) Migraine Recurrence Rates: case for Standardization of the Definition. J Headache Pain 11(Suppl 1):471. https:\/\/doi.org\/10.1007\/s10194-010-0259-3","journal-title":"J Headache Pain"},{"key":"1519_CR20","unstructured":"DCAT (2014) Allergan receives FDA complete response letter for migraine drug semprana. https:\/\/www.dcatvci.org\/top-industry-news\/allergan-receives-fda-complete-response-letter-for-migraine-drug-semprana\/. Accessed 22 Feb\u00a02022."},{"key":"1519_CR21","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s10194-009-0144-0","volume":"10","author":"P Tfelt-Hansen","year":"2009","unstructured":"Tfelt-Hansen P (2009) What can be learned from the history of recurrence in migraine? A comment. J Headache Pain 10:311\u2013315. https:\/\/doi.org\/10.1007\/s10194-009-0144-0","journal-title":"J Headache Pain"},{"key":"1519_CR22","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1159\/000116757","volume":"31","author":"AJ Pilgrim","year":"1991","unstructured":"Pilgrim AJ (1991) Methodology of clinical trials of sumatriptan in migraine and cluster headache. Eur Neurol 31:295\u2013299. https:\/\/doi.org\/10.1159\/000116757","journal-title":"Eur Neurol"},{"key":"1519_CR23","doi-asserted-by":"publisher","unstructured":"International Headache Society Committee on Clinical Trials in Migraine (1991) Guidelines for controlled trials of drugs in migraine. First edition. International Headache Society Committee on Clinical Trials in Migraine. 11:1\u201312. https:\/\/doi.org\/10.1046\/j.1468-2982.1991.1101001.x.","DOI":"10.1046\/j.1468-2982.1991.1101001.x"},{"key":"1519_CR24","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.2165\/00003495-200060060-00003","volume":"60","author":"P Tfelt-Hansen","year":"2000","unstructured":"Tfelt-Hansen P, De Vries P, Saxena PR (2000) Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 60:1259\u20131287. https:\/\/doi.org\/10.2165\/00003495-200060060-00003","journal-title":"Drugs"},{"key":"1519_CR25","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2147\/ndt.s1871","volume":"4","author":"L Kelman","year":"2008","unstructured":"Kelman L (2008) Review of frovatriptan in the treatment of migraine. Neuropsychiatr Dis Treat 4:49\u201354. https:\/\/doi.org\/10.2147\/ndt.s1871","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"Suppl 2","key":"1519_CR26","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1046\/j.1526-4610.42.s2.6.x","volume":"42","author":"R Ryan","year":"2002","unstructured":"Ryan R, G\u00e9raud G, Goldstein J, Cady R, Keywood C (2002) Clinical efficacy of frovatriptan: Placebo-controlled studies. Headache 42(Suppl 2):S84-92. https:\/\/doi.org\/10.1046\/j.1526-4610.42.s2.6.x","journal-title":"Headache"},{"key":"1519_CR27","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1046\/j.1468-2982.1994.1405330.x","volume":"14","author":"MD Ferrari","year":"1994","unstructured":"Ferrari MD, James MH, Bates D, Pilgrim A, Ashford E, Anderson BA et al (1994) Oral sumatriptan: Effect of a second dose, and incidence and treatment of headache recurrences. Cephalalgia 14:330\u2013338. https:\/\/doi.org\/10.1046\/j.1468-2982.1994.1405330.x","journal-title":"Cephalalgia"},{"key":"1519_CR28","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/030006059502300202","volume":"23","author":"LA Pini","year":"1995","unstructured":"Pini LA, Sternieri E, Fabbri L, Zerbini O, Bamfi F (1995) High efficacy and low frequency of headache recurrence after oral sumatriptan. The Oral Sumatriptan Italian Study Group. J Int Med Res 23:96\u2013105. https:\/\/doi.org\/10.1177\/030006059502300202","journal-title":"J Int Med Res"},{"key":"1519_CR29","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12883-019-1420-5","volume":"19","author":"LS Loo","year":"2019","unstructured":"Loo LS, Plato BM, Turner IM, Case MG, Raskin J, Dowsett SA et al (2019) Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN). BMC Neurol 19:191. https:\/\/doi.org\/10.1186\/s12883-019-1420-5","journal-title":"BMC Neurol"},{"key":"1519_CR30","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1177\/0333102419864132","volume":"39","author":"JL Brandes","year":"2019","unstructured":"Brandes JL, Klise S, Krege JH, Case M, Khanna R, Vasudeva R et al (2019) Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study). Cephalalgia 39:1343\u20131357. https:\/\/doi.org\/10.1177\/0333102419864132","journal-title":"Cephalalgia"},{"key":"1519_CR31","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/s0140-6736(19)31606-x","volume":"394","author":"R Croop","year":"2019","unstructured":"Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG et al (2019) Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet 394:737\u2013745. https:\/\/doi.org\/10.1016\/s0140-6736(19)31606-x","journal-title":"Lancet"},{"key":"1519_CR32","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","volume":"381","author":"DW Dodick","year":"2019","unstructured":"Dodick DW, Lipton RB, Ailani J, Lu K, Finnegan M, Trugman JM et al (2019) Ubrogepant for the treatment of migraine. N Engl J Med 381:2230\u20132241. https:\/\/doi.org\/10.1056\/NEJMoa1813049","journal-title":"N Engl J Med"},{"key":"1519_CR33","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1001\/jama.2019.16711","volume":"322","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Dodick DW, Ailani J, Lu K, Finnegan M, Szegedi A et al (2019) Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA 322:1887\u20131898. https:\/\/doi.org\/10.1001\/jama.2019.16711","journal-title":"JAMA"},{"key":"1519_CR34","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1111\/head.14184","volume":"61","author":"TR Smith","year":"2021","unstructured":"Smith TR, Winner P, Aurora SK, Jeleva M, Hocevar-Trnka J, Shrewsbury SB (2021) STOP 301: a Phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD\u00ae) of dihydroergotamine mesylate, over 24\/52 weeks in acute treatment of migraine attacks in adult patients. Headache 61:1214\u20131226. https:\/\/doi.org\/10.1111\/head.14184","journal-title":"Headache"},{"issue":"Suppl 4","key":"1519_CR35","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/head.12601","volume":"55","author":"C Cameron","year":"2015","unstructured":"Cameron C, Kelly S, Hsieh SC, Murphy M, Chen L, Kotb A et al (2015) Triptans in the acute treatment of migraine: a systematic review and network meta-analysis. Headache 55(Suppl 4):221\u2013235. https:\/\/doi.org\/10.1111\/head.12601","journal-title":"Headache"},{"key":"1519_CR36","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1046\/j.1526-4610.2003.03073.x","volume":"43","author":"G G\u00e9raud","year":"2003","unstructured":"G\u00e9raud G, Keywood C, Senard JM (2003) Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache 43:376\u2013388. https:\/\/doi.org\/10.1046\/j.1526-4610.2003.03073.x","journal-title":"Headache"},{"key":"1519_CR37","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1046\/j.1468-2982.1996.1604264.x","volume":"16","author":"WH Visser","year":"1996","unstructured":"Visser WH, Jaspers NM, de Vriend RH, Ferrari MD (1996) Risk factors for headache recurrence after sumatriptan: a study in 366 migraine patients. Cephalalgia 16:264\u2013269. https:\/\/doi.org\/10.1046\/j.1468-2982.1996.1604264.x","journal-title":"Cephalalgia"},{"key":"1519_CR38","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1111\/j.1526-4610.2008.01244.x","volume":"48","author":"P Tfelt-Hansen","year":"2008","unstructured":"Tfelt-Hansen P (2008) Frovatriptan and data publication. Headache 48:1382\u20131383. https:\/\/doi.org\/10.1111\/j.1526-4610.2008.01244.x","journal-title":"Headache"},{"key":"1519_CR39","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1159\/000008094","volume":"42","author":"M Bomhof","year":"1999","unstructured":"Bomhof M, Paz J, Legg N, Allen C, Vandormael K, Patel K (1999) Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine. Eur Neurol 42:173\u2013179. https:\/\/doi.org\/10.1159\/000008094","journal-title":"Eur Neurol"},{"key":"1519_CR40","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/head.13700","volume":"60","author":"SD Silberstein","year":"2020","unstructured":"Silberstein SD, Shrewsbury SB, Hoekman J (2020) Dihydroergotamine (DHE) \u2013 then and now: a narrative review. Headache 60:40\u201357. https:\/\/doi.org\/10.1111\/head.13700","journal-title":"Headache"},{"key":"1519_CR41","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1111\/j.1526-4610.2009.01510.x","volume":"49","author":"RO Cook","year":"2009","unstructured":"Cook RO, Shrewsbury SB, Ramadan NM (2009) Reduced adverse event profile of orally inhaled DHE (MAP0004) vs IV DHE: potential mechanism. Headache 49:1423\u20131434. https:\/\/doi.org\/10.1111\/j.1526-4610.2009.01510.x","journal-title":"Headache"},{"key":"1519_CR42","doi-asserted-by":"publisher","first-page":"702","DOI":"10.4065\/74.7.702","volume":"74","author":"JD Bartleson","year":"1999","unstructured":"Bartleson JD (1999) Treatment of migraine headaches. Mayo Clin Proc 74:702\u2013708. https:\/\/doi.org\/10.4065\/74.7.702","journal-title":"Mayo Clin Proc"},{"key":"1519_CR43","unstructured":"Kori S (2010) LEVADEX\u2122 efficacy in treating resistant migraine. Ann Neurol 68:M\u201348"},{"issue":"Suppl 1","key":"1519_CR44","doi-asserted-by":"publisher","first-page":"P143","DOI":"10.1186\/1129-2377-14-S1-P143","volume":"14","author":"S Aurora","year":"2013","unstructured":"Aurora S, Lu B, Connors E, Li X, Kellerman D, Kori S (2013) Analysis of subjects with menstrually related migraine vs. non-menstrually related migraine treated with MAP0004. J Headache Pain 14(Suppl 1):P143. https:\/\/doi.org\/10.1186\/1129-2377-14-S1-P143","journal-title":"J Headache Pain"},{"key":"1519_CR45","doi-asserted-by":"publisher","first-page":"948","DOI":"10.4065\/mcp.2011.0093","volume":"86","author":"SJ Tepper","year":"2011","unstructured":"Tepper SJ, Kori SH, Goadsby PJ, Winner PK, Wang MH, Silberstein SD et al (2011) MAP0004, orally inhaled dihydroergotamine for acute treatment of migraine: efficacy of early and late treatments. Mayo Clin Proc 86:948\u2013955. https:\/\/doi.org\/10.4065\/mcp.2011.0093","journal-title":"Mayo Clin Proc"},{"key":"1519_CR46","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1526-4610.2011.02041.x","volume":"52","author":"SJ Tepper","year":"2012","unstructured":"Tepper SJ, Kori SH, Borland SW, Wang MH, Hu B, Mathew NT et al (2012) Efficacy and safety of MAP0004, orally inhaled DHE in treating migraines with and without allodynia. Headache 52:37\u201347. https:\/\/doi.org\/10.1111\/j.1526-4610.2011.02041.x","journal-title":"Headache"},{"key":"1519_CR47","unstructured":"TRUDHESA [prescribing information] (2021)\u00a0Impel NeuroPharma Inc., Seattle.\u00a0https:\/\/trudhesa.com\/trudhesa-prescribing-information.pdf. Accessed 2 Feb 2022."},{"key":"1519_CR48","unstructured":"MIGRANAL [prescribing information] (2019)\u00a0Bausch Health Companies, Inc;\u00a0https:\/\/www.bauschhealth.com\/Portals\/25\/Pdf\/PI\/Migranal-PI.pdf. Accessed 2 Feb 2022."},{"issue":"Suppl 1","key":"1519_CR49","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1111\/j.1526-4610.2008.01172.x","volume":"48","author":"SH Kori","year":"2008","unstructured":"Kori SH, Shrewsbury SB (2008) Newer acute migraine specific drugs may provide improved sustained relief and freedom over 24 and 48 hours post dosing. Headache 48(Suppl 1):S1-67. S12. https:\/\/doi.org\/10.1111\/j.1526-4610.2008.01172.x","journal-title":"Headache"},{"key":"1519_CR50","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1111\/head.13791","volume":"60","author":"D Tepper","year":"2020","unstructured":"Tepper D (2020) Gepants. Headache 60:1037\u20131039. https:\/\/doi.org\/10.1111\/head.13791","journal-title":"Gepants Headache"},{"key":"1519_CR51","unstructured":"Ubrelvy [prescribing information] (2021)\u00a0Allergan USA, Inc, Madison.\u00a0https:\/\/media.allergan.com\/products\/Ubrelvy_pi.pdf. Accessed 2 Feb 2022."},{"key":"1519_CR52","doi-asserted-by":"publisher","first-page":"e2222","DOI":"10.1212\/wnl.0000000000006641","volume":"91","author":"B Kuca","year":"2018","unstructured":"Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB et al (2018) Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized study. Neurology 91:e2222-2232. https:\/\/doi.org\/10.1212\/wnl.0000000000006641","journal-title":"Neurology"},{"key":"1519_CR53","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1093\/brain\/awz134","volume":"142","author":"PJ Goadsby","year":"2019","unstructured":"Goadsby PJ, Wietecha LA, Dennehy EB, Kuca B, Case MG, Aurora SK et al (2019) Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain 142:1894\u20131904. https:\/\/doi.org\/10.1093\/brain\/awz134","journal-title":"Brain"},{"key":"1519_CR54","unstructured":"Lilly Investors (2020) Lilly's REYVOW\u2122 (lasmiditan) C-V, the first and only medicine in a new class of acute treatment for migraine (ditan), now available for prescription. News release. https:\/\/www.investor.lilly.com\/news-releases\/news-release-details\/lillys-reyvowtm-lasmiditan-c-v-first-and-only-medicine-new-class. Accessed 2 Feb 2022."},{"key":"1519_CR55","unstructured":"Reyvow [prescribing information] (2021)\u00a0Eli Lilly and Company, Indianapolis.\u00a0http:\/\/pi.lilly.com\/us\/reyvow-uspi.pdf. Accessed 2 Feb 2022."}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01519-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-022-01519-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01519-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T01:27:43Z","timestamp":1669166863000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-022-01519-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,22]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1519"],"URL":"https:\/\/doi.org\/10.1186\/s10194-022-01519-4","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,22]]},"assertion":[{"value":"15 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Stewart J. Tepper has received grants for research (no personal compensation) from Allergan\/AbbVie, Amgen, Eli Lilly and Company, Lundbeck, Neurolief, Novartis, Satsuma, and Zosano. He has consulted with and\/or participated in advisory boards (honoraria) for Aeon, Allergan\/AbbVie, AlphaSights, Amgen, Atheneum, Axsome Therapeutics, Becker Pharmaceuticals, ClearView Healthcare Partners, CoolTech, CRG, Currax, DRG, Eli Lilly and Company, Equinox, ExpertConnect, FCB Health, GLG, Guidepoint Global, Health Science Communications, HMP Communications, Impel Pharmaceuticals, Interactive Forums, Krog and Partners, Lundbeck, M3 Global Research, MJH Holdings, Neurolief, Novartis, Palion Medical, Pulmatrix, SAI MedPartners, Satsuma, Spherix Global Insights, Strategy Inc, System Analytic, Taylor & Francis, Teva, Theranica, Unity HA, Xoc, and Zosano. He receives a salary from Dartmouth-Hitchcock Medical Center, American Headache Society, and Thomas Jefferson University. He has received CME honoraria from the American Academy of Neurology, American Headache Society, Annenberg Center for Health Sciences, Catamount Medical Education, Diamond Headache Clinic, Forefront Collaborative, Haymarket Medical Education, Medical Education Speakers Network, National Association for Continuing Education, North American Center for\u00a0CME, The Ohio State University, PeerView, Physicians\u2019 Education Resource, PlatformQ Education, PriMed, Texas Neurological Society, and WebMD\/Medscape. Jessica Ailani has received honoraria for consulting from AbbVie, Aeon, Amgen, Axsome, Biohaven, Eli Lilly and Company, GlaxoSmithKline, Impel Pharmaceuticals, Lundbeck, N\u0113sos, Satsuma, and Teva. She has received stock options from Ctrl M Health for consulting. She has received honoraria for speaking engagements from AbbVie, Amgen, Biohaven, Eli Lilly and Company, Lundbeck, and Teva. Jessica Ailani\u2019s institution has received funding for clinical trials for her work as principal investigator from Allergan\/AbbVie, Biohaven, Eli Lilly and Company, Satsuma, and Zosano. She has provided advising and editorial services for, and has received honoraria from, <i>Current Pain and Headache Reports<\/i>, Medscape, Neurology Live, and <i>SELF<\/i>. Sheena K. Aurora, Sutapa Ray, and Stephen B. Shrewsbury are full-time employees of Impel Pharmaceuticals and are stockholders in Impel Pharmaceuticals. Stephen B. Shrewsbury is an officer of Impel Pharmaceuticals. Joe Hirman is a paid consultant for Impel Pharmaceuticals.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"148"}}